SL-401: Additional Phase II data

Data from 19 evaluable patients with BPDCN in an open-label, U.S. Phase II trial showed that SL-401

Read the full 177 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE